A Phase II Trial of PS-341 in Combination With Paclitaxel and Carboplatin for Metastatic Adenocarcinoma of the Lower Esophagus, Gastroesophageal Junction, and Gastric Cardia.

Trial Profile

A Phase II Trial of PS-341 in Combination With Paclitaxel and Carboplatin for Metastatic Adenocarcinoma of the Lower Esophagus, Gastroesophageal Junction, and Gastric Cardia.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Bortezomib (Primary) ; Carboplatin; Paclitaxel
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
    • 15 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top